ProSci’s custom antibody service played a crucial role in the recent study conducted by the Genome Protection and Roswell Park Comprehensive Cancer Center titled “Cancer relevance of circulating antibodies against LINE-1 antigens in humans ” 1.
Long interspersed nuclear element-1 (LINE-1 or L1) is a non-LTR retrotransposon with multiple copies accumulated during mammalian evolution 2. LINE-1 occupies ~17% of human DNA 3 and is typically silenced in normal tissues but is active in various cancers 4.
LINE-1 encode two polypeptides, open reading frame 1 (ORF1p) and 2 (ORF2p), and an immune response to L1 antigens was observed in early cancer stages, suggesting L1 antigens could aid in cancer diagnosis and determining tumor immunoreactivity 5,6,7.
The study examined possible cancer biomarkers and tumor immune responses by identifying antibodies against LINE-1 antigens through the ABLE (antibodies to L1 detected by ELISA) assay. This immunoassay was created to detect antibodies against L1 antigens in human blood samples, offering the potential to identify early and advanced stages of various cancers and tumor immune reactions 1.
The study’s findings revealed that the levels of anti-ORF1p IgG were significantly higher in cancer patients compared to healthy individuals. In contrast, anti-ORF2p IgG levels did not display a significant difference. Additionally, anti-p53 IgG levels were notably elevated in cancer patients and showed a weak correlation with anti-ORF1p IgG levels. This suggests that anti-ORF1p antibodies may be useful in cancer detection and assessing tumor immune responses 1.
ProSci’s custom antibody service was used to generate anti-ORF2p rat affinity-purified polyclonal antibodies used in this study.
“We used ProSci’s custom anybody service to generate anti-ORF2p rat affinity-purified polyclonal antibodies used in this study. ProSci made anti-ORF2p rat affinity-purified polyclonal antibodies in accordance with our requirements and on time. Polyclonal antibodies were high quality, with desired specificity and we are very satisfied with the service” – Dr. Alexandra Vylegzhanina
The use of ProSci’s custom antibody service in the study highlights the importance of customizable services in developing novel research tools for scientific discovery. The high-quality custom antibody services provided by ProSci assisted the researchers allowing them to
- Work with experts to design and produce an antibody that is specifically fit for their application. This custom antibody was optimized to increase the ABLE assay’s sensitivity and reduce background to detect circulating L1 antibodies, which led to accurate and reproducible results.
- Accelerated antibody development and production timeline, enabling researchers to focus on their core research and achieve results faster.
- Release their findings for pre-print.
ProSci’s custom antibody service provides researchers worldwide with an ideal partner for developing customized research tools for scientific discovery, including potential biomarkers for cancer detection and tumor immunoreactivity. When commercially available antibodies are not suitable for unique applications, custom antibody services provide researchers a solution to generate robust scientific data.
ProSci’s custom antibody services specialize in polyclonal, monoclonal, and recombinant rabbit monoclonal and recombinant llama single-domain antibody development and production. With over 20,000 individual antibody projects completed and in-house research programs, ProSci is well-equipped to deliver antibodies that meet the needs of researchers worldwide.
ProSci Incorporated, now part of the Genesee Scientific Family, is a biotechnology company that provides high-quality antibody products and services, including monoclonal, polyclonal, and recombinant antibody production. Our customizable services include antigen design, peptide synthesis, protein conjugation, and antibody development. ProSci has an impressive catalog of over 30,000 primary antibodies, many of which are affinity-purified to isolate antibodies specific to the epitope of interest, making them ideal for research applications.
- Vylegzhanina AV et al. Cancer relevance of circulating antibodies against LINE-1 antigens in humans. bioRxiv 2023.02.03.526997. doi.org/10.1101/2023.02.03.526997
- Ostertag EM, Kazazian HH Jr. Biology of mammalian L1 retrotransposons. Annu Rev Genet. 2001;35:501-38.
- Lander ES, Linton LM, Birren B, et al., International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001 Feb 15;409(6822):860-921.
- Rodić N, Burns KH. Long Interspersed Element-1 (LINE-1): Passenger or Driver in Human Neoplasms? PLoS Genet. 2013;9(3):e1003402.
- Ardeljan D, Wang X, Oghbaie M, Taylor MS, Husband D, Deshpande V, Steranka JP, Gorbounov M, Yang WR, Sie B, Larman HB, Jiang H, Molloy KR, Altukhov I, Li Z, McKerrow W, Fenyö D, Burns KH, LaCava J. LINE-1 ORF2p expression is nearly imperceptible in human cancers. Mob DNA. 2019 Dec 31;11:1.
- Sharp CN, Korte EA, Hosseinejad K, Pitman J, Lavasanifar A, Eichenberger DJ, Sephton S, Cash E, Jortani SA. ELISA-based detection of Open Reading Frame protein 1 in patients at risk of developing lung cancer. Clin Chim Acta. 2020 Aug;507:1-6.
- Hosseinnejad K, Yin T, Gaskins JT, Bailen JL, Jortani SA. Discovery of the Long Interspersed Nuclear Element-1 activation product [Open Reading Frame-1 (ORF1) protein] in human blood. Clin Chim Acta. 2018 Dec;487:228-232